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Antigenic Targets and Pathogenicity of
Anti–Aortic Endothelial Cell Antibodies in Takayasu Arteritis
Sunil Kumar Chauhan, Naresh Kumar Tripathy, and Soniya Nityanand
Objective. Anti–endothelial cell antibodies are
considered to have an important role in the pathogene-
sis of Takayasu arteritis (TA). Previously, these anti-
bodies were detected using human umbilical vein endo-
thelial cells, which do not completely represent the
antigenicity/functions of aortic endothelial cells, the
specific targets in TA. To delineate the precise role of
antigenic targets, we investigated such targets as well as
the pathogenic mechanism of antibodies directed
against aortic endothelial cells (AAECAs) in TA.
Methods. AAECAs were detected using a cellular
enzyme-linked immunosorbent assay (ELISA), and
their antigenic targets were detected by immunoblot-
ting. AAECA-mediated induction of endothelial adhe-
sion molecule expression and cytokine production was
studied by ELISA, and apoptosis was studied using the
TUNEL method.
Results. AAECAs were detected in 86% of patients
with TA and in 9% of controls. Sera obtained from
AAECA-positive patients with TA recognized a total of 9
antigens ranging in size from 18 kd to 200 kd, of which
the 60–65-kd triplet was recognized most often. The
aortic endothelial cell reactivity of Hsp60-absorbed sera
was reduced by 50% as compared with that of unab-
sorbed sera (mean  SD 0.488  0.08 versus 0.838 
0.116). Sera from AAECA-positive patients with TA,
compared with sera from AAECA-negative patients with
TA and that from controls, induced increased expres-
sion of E-selectin (mean  SD 0.833  0.063 versus
0.217  0.081 and 0.221  0.101 optical density [OD]
units, respectively) and vascular cell adhesion molecule
1 (0.620 0.144 versus 0.165 0.005 and 0.177 0.055
OD units, respectively) and increased production of
interleukin-4 (IL-4) (6.8  2.4 versus 1.2  1.6 and
1.3  2.5 pg/ml, respectively), IL-6 (24.3  2.4 versus
4.5  6.7 and 5.9  5.1 pg/ml, respectively), and IL-8
(36.8  10.3 versus 10.1  6.7 and 7.8  2.1 pg/ml,
respectively). Sera from AAECA-positive patients with
TA induced 29  6% (median  SEM) apoptosis of
aortic endothelial cells.
Conclusion. Our data show that the AAECAs that
are present in patients with TA are directed mainly
against 60–65-kd antigen(s) and may cause vascular
dysfunction by inducing expression of endothelial adhe-
sion molecules, cytokine production, and apoptosis.
Takayasu arteritis (TA) is a chronic granuloma-
tous inflammatory arteriopathy that affects primarily
large elastic arteries, mainly the aorta and its major
branches. TA is characterized by stenosis, occlusion, or
aneurysm of the involved arteries that eventually results
in different clinical manifestations of the disease (1,2).
TA has an autoimmune etiology, and immune-mediated
dysfunction of aortic endothelium is considered to be
the key event in the pathogenesis of the disease (3,4).
Immunoglobulin deposits in vascular lesions and
the presence of circulating antibodies to human umbili-
cal vein endothelial cells (HUVECs) (anti–endothelial
cell antibodies [AECAs]) and their correlation with
disease activity suggest that AECAs may be an impor-
tant immune component involved in the development of
TA (5–7). These antibodies may cause vascular dysfunc-
tion through multiple mechanisms, including up-
regulation of endothelial adhesion molecules and induc-
tion of cytochemokine production by endothelial cells,
or through direct endothelial damage by apoptosis or
other mechanisms (8). However, very limited informa-
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tion is available about the antigenic targets and precise
pathogenic mechanism(s) of AECAs in TA. Further-
more, previous studies in TA have used HUVECs, which
are fetal tissue–derived endothelial cells. Although
HUVECs may have certain characteristics in common
with aortic endothelial cells, they may not completely
represent the antigenic and functional profile of those
cells (9,10), which are specifically targeted in TA. Thus,
in view of the type of vessel affected in TA, aortic
endothelial cells would be the most clinically relevant
target for studying the role of AECAs in TA. Until now,
however, no study on AECAs directed against aortic
endothelial cells (AAECAs) in TA has been available.
In the present study, we investigated antigenic
targets of AAECAs and the induction of endothelial
adhesion molecule expression, cytokine production, and
apoptosis by these antibodies, in order to understand
their pathogenic mechanism in TA.
PATIENTS AND METHODS
Patients. The study group comprised 35 patients with
TA (25 women and 10 men; mean age 26 years [range 14–47
years]) and 21 age- and sex-matched healthy controls. The
study was approved by the Institutional Ethics Committee of
Sanjay Gandhi Postgraduate Institute of Medical Sciences.
The diagnosis of TA was established on the basis of clinical,
laboratory, and angiographic findings. All patients fulfilled the
American College of Rheumatology 1990 criteria for a diag-
nosis of TA and had angiographically proven disease (11). The
disease activity of the patients was determined according to
previously described criteria (12). Accordingly, 14 patients had
active TA, and 21 patients had inactive TA. The patients with
active TA were assigned to an immunosuppressive regimen
consisting of 1 mg/kg/day of prednisolone and 2 mg/kg/day of
azathioprine. Once disease became inactive, patients received
maintenance dosages of prednisolone (5–10 mg/day) and aza-
thioprine (2 mg/kg/day). Immunosuppressive therapy was
given for a period of 2 years.
After informed consent was obtained, 5 ml of venous
blood was collected from each individual, and isolated serum
was stored at 80°C until analyzed. Sera from all patients and
controls were used for detecting AAECAs, whereas 10 high-
titer AAECA-positive TA sera, 5 AAECA-negative TA sera,
and 12 control sera (including 2 AAECA-positive sera) were
used for immunoblotting and functional studies.
Culture of aortic endothelial cells. Normal human
aortic endothelial cells and cell culture reagents were procured
from Cambrex Bioscience (Walkersville, MD). Cells were
cultured under standard conditions, and subcultures of pas-
sages 4–6 were used for the experiments.
Detection of AAECAs. AAECAs were detected by
cellular enzyme-linked immunosorbent assay (ELISA), as de-
scribed previously (6). Briefly, aortic endothelial cells were
seeded in 96-well culture plates to obtain a monolayer of cells.
The cells were washed twice with phosphate buffered saline
(PBS) and fixed with 0.2% glutaraldehyde and 0.2% Triton
X-100 for 20 minutes. After blocking nonspecific binding sites
with 5% bovine serum albumin (BSA), test serum diluted 1:100
was added at 100 l/well and incubated for 2 hours at 37°C.
The bound antibodies were detected with goat anti-human IgG
peroxidase-conjugated antibodies (Dako, Kyoto, Japan), using
tetramethylbenzidine substrate. Washings between steps were
performed with PBS containing 0.5% BSA. Optical density
(OD) was measured at 450 nm in an automated ELISA reader
(Spectra; Tecan, Gro¨dig, Austria). OD values greater than the
mean  2 SD value of the normal controls were considered
positive.
Characterization of antigenic targets of AAECAs. The
antigenic targets of AAECAs were characterized by Western
blotting, as described elsewhere (13). A monolayer of aortic
endothelial cells washed twice with PBS was harvested by
scraping with a rubber scraper. The cells were mixed with lysis
buffer and incubated for 20 minutes on ice to ensure homo-
geneous solubilization. The lysate was spun at 12,000 revolu-
tions per minute for 15 minutes, and the supernatants obtained
were subjected to electrophoresis on 10% sodium dodecyl
sulfate–polyacrylamide gels. Proteins were electrotransferred
from the gels onto a polyvinylidene difluoride membrane.
Nonspecific binding sites on the membrane were blocked with
5% BSA for 2 hours at 37°C. The membrane was cut into strips
and incubated overnight with serum samples diluted 1:10. The
strips were then incubated for 90 minutes with goat anti-
human IgG peroxidase-conjugated antibody (Dako), and color
was developed with diaminobenzidine (Bio-Rad, Hercules,
CA).
Determination of absorption of Hsp60 activity of sera.
To determine whether Hsp60 is one of the target antigens of
AAECAs on aortic endothelial cells, we performed an absorp-
tion study using sera from 10 patients with TA that contained
high titers of AAECAs. The sera were diluted 1:100 and
incubated for 1 hour at 37°C in 5 successive wells coated with
Hsp60 (10 g/ml), and the endothelial reactivity of these
absorbed and unabsorbed sera was determined by cellular
ELISA using aortic endothelial cells, as described above.
Detection of AAECA-induced E-selectin and vascular
cell adhesion molecule 1 (VCAM-1) expression. Aortic endo-
thelial cells grown in 96-well culture plates were incubated with
test sera (diluted 1:10) for 24 hours at 37°C. Thereafter, culture
was terminated, and cellular ELISA (as previously described
for detection of AAECAs) was performed for detection of
AAECA-induced E-selectin and VCAM-1 expression, by using
peroxidase-conjugated mouse anti-human E-selectin/VCAM-1
antibodies (R&D Systems, Minneapolis, MN).
Detection of AAECA-induced cytokine production.
Aortic endothelial cells grown in 96-well culture plates were
incubated with test sera (diluted 1:10) for 24 hours at 37°C.
The supernatant from individual wells was collected to evalu-
ate cytokine production by the cells. The detection of cytokines
(interleukin-4 [IL-4], IL-6, IL-8, IL-10, and tumor necrosis
factor  [TNF]) in the supernatant was performed using
commercial kits (BD Biosciences, San Jose, CA), according to
the manufacturer’s instructions.
Detection of AAECA-induced apoptosis. Aortic endo-
thelial cells grown in 24-well culture plates were incubated with
test sera (diluted 1:10) for 24 hours, and apoptosis in the
harvested cells was detected by the TUNEL method, using the
ApoDIRECT flow cytometry kit (BD Biosciences) (14). Cells
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were analyzed in a single-parameter histogram showing fluo-
rescein isothiocyanate–dUTP on the x-axis and the relative cell
number on the y-axis, using CellQuest software (CellQuest,
Largo, FL). Cells in the M1 gate were regarded as being
negative cells, whereas the presence of apoptotic cells was
demonstrated in the M2 gate.
Statistical analysis. Statistical analysis was performed
using the Mann-Whitney U test for the comparison of means
and Fisher’s exact test for the analysis of frequency. Data are
expressed as the mean  SD or median  SEM. P values
(2-tailed) less than 0.05 were considered significant.
RESULTS
Prevalence of AAECAs. AAECAs were observed
in the sera of 30 (86%) of 35 patients with TA compared
with 2 (9%) of 21 healthy controls (P  0.001). The
levels of AAECAs were also significantly higher in
patients compared with healthy controls (0.819  0.429
versus 0.288 0.111; P 0.001). However, there was no
difference in the prevalence of AAECAs in patients with
active TA (12 [86%] of 14) and those in whom TA was
inactive (18 [86%] of 21). Similarly, no difference in the
levels of AAECAs was observed between patients with
active TA and those with inactive TA (0.952  0.524
versus 0.735  0.332; P  0.219) (Figure 1).
Antigenic targets of AAECAs. The molecular
weights of proteins recognized by AAECAs from differ-
ent groups of study subjects are shown in Table 1, and
their representative immunoblots are shown in Figure 2.
Sera obtained from AAECA-positive patients reacted
with 3–5 of 9 aortic endothelial cell antigens ranging
from 18 kd to 200 kd. The most common reactivity was
against a triplet of bands ranging from 60 kd to 65 kd. No
protein bands were recognized by AAECA-negative TA
Figure 1. Dot plot showing levels of anti–aortic endothelial cell
antibodies (AAECAs) in all patients with Takayasu arteritis (TA),
patients with active TA (aTA), patients with inactive TA (iTA), and
healthy controls (HC). Each dot represents the data for an individual
subject. The solid horizontal lines show the means. The broken
horizontal line represents the cutoff limit (mean  2 SD of values in
the control group). OD  optical density.
Figure 2. Representative immunoblots showing the molecular
weights of different protein bands recognized by sera from anti–aortic
endothelial cell antibody (AAECA)–positive patients with Takayasu
arteritis (TA) (lanes 1–5), AAECA-negative patients with TA (lanes 6
and 7), and healthy controls (lanes 8–10). M  molecular weight
marker; CL  cell lysate of aortic endothelial cells.
Table 1. Molecular weights and frequency of antigenic targets rec-
ognized by AAECAs in patients with TA and healthy controls*
Group/antigenic target
Frequency of
recognition
AAECA-positive patients (n  10)
18 kd 2/10
21 kd 3/10
27 kd 5/10
28 kd 4/10
32 kd 6/10
44 kd 1/10
60–65 kd 10/10
80 kd 3/10
200 kd 6/10
AAECA-negative patients (n  5)
NA NA
Healthy controls (n  12)
27 kd and 28 kd 1/12
* AAECAs  anti–aortic endothelial cell antibodies; TA  Takayasu
arteritis. NA  not applicable.
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sera. Similarly, sera from healthy controls did not rec-
ognize any of the protein bands, with the exception that
1 of the AAECA-positive sera showed reactivity to a
doublet corresponding to 27-kd and 28-kd antigens.
Absorption of Hsp60 activity of sera. The aortic
endothelial cell reactivity of Hsp60-absorbed sera was
reduced by 50% as compared with that of unabsorbed
sera (0.488  0.08 versus 0.838  0.116; P  0.009).
AAECA-induced E-selectin and VCAM-1 expres-
sion. All AAECA-positive TA sera, but none of the
AAECA-negative TA sera or control sera up-regulated
Figure 3. Dot plots showing expression of E-selectin (a) and vascular
cell adhesion molecule 1 (VCAM-1) (b) by aortic endothelial cells
stimulated with sera from anti–aortic endothelial cell antibody
(AAECA)–positive patients with Takayasu arteritis (TA), AAECA-
negative patients with TA, and healthy controls (HC). Horizontal lines
represent the means. OD  optical density.
Figure 4. Dot plots showing production of interleukin-4 (IL-4) (a),
IL-6 (b), and IL-8 (c) by aortic endothelial cells stimulated with sera
from anti–aortic endothelial cell antibody (AAECA)–positive patients
with Takayasu arteritis (TA), AAECA-negative patients with TA, and
healthy controls (HC). Horizontal lines represent the means.
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the expression of E-selectin and VCAM-1 by aortic
endothelial cells. Sera from AAECA-positive patients
with TA, compared with sera from AAECA-negative
patients with TA and healthy controls, induced signifi-
cantly increased expression of E-selectin (0.833  0.063
versus 0.217  0.081 and 0.221  0.101 OD units,
respectively; P  0.002 and P  0.001, respectively) and
VCAM-1 (0.620  0.144 versus 0.165  0.005 and
0.177 0.055 OD units, respectively; P 0.002 and P
0.001, respectively) (Figure 3).
AAECA-induced cytokine production. Sera from
AAECA-positive patients with TA, compared with sera
from AAECA-negative patients with TA and healthy
controls, significantly increased cytokine production
by aortic endothelial cells (for IL-4, 6.8  2.4 versus
1.2  1.6 and 1.3  2.5 pg/ml, respectively [P  0.002
and P  0.001, respectively]; for IL-6, 24.3  2.4 versus
4.5  6.7 and 5.9  5.1 pg/ml, respectively [P  0.007
and P  0.001, respectively]; and for IL-8, 36.8  10.3
versus 10.1  6.7 and 7.8  2.1 pg/ml, respectively
[P  0.003 and P  0.001, respectively]) (Figure 4). In
contrast, production of IL-10 and TNF by aortic
endothelial cells was undetectable in all of the study
groups.
AAECA-induced apoptosis. All AAECA-positive
TA sera induced apoptosis in aortic endothelial cells,
whereas no apoptosis of cells was observed in any of the
AAECA-negative TA sera and control sera, with the
exception of AAECA-positive control sera, which in-
duced 16% apoptosis. The magnitude of apoptosis in
aortic endothelial cells induced by the sera of AAECA-
positive patients with TA was a median SEM 29 6%
(Figure 5). Baseline apoptosis in untreated aortic endo-
thelial cells was observed to be 6%.
Figure 5. Representative flow cytometry histograms (a) and dot plots (b) showing endothelial cell apoptosis induced by sera
from anti–aortic endothelial cell antibody (AAECA)–positive patients with Takayasu arteritis (TA), AAECA-negative patients
with TA, and healthy controls (HC). Percentages in a indicate the proportion of apoptotic cells. Horizontal lines in b represent
the medians. FITC  fluorescein isothiocyanate.
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DISCUSSION
Our study shows that most patients with TA have
circulating AAECAs, which are directed predominantly
to a triplet of aortic endothelial cell antigens ranging in
size from 60 kd to 65 kd. These AAECAs induce
adhesion molecule expression and inflammatory cyto-
kine production by aortic endothelial cells and cause
apoptosis of aortic endothelial cells. To our knowledge,
this study is the first to explore the prevalence, antigenic
targets, and pathogenicity of AAECAs in TA.
Previous studies using HUVECs as antigenic
substrate have shown the prevalence of AECAs in a
larger proportion of patients with active TA. We previ-
ously reported the overall prevalence of AECAs to be
33% in patients with TA, 62% in patients with active TA,
and 18% in patients with inactive TA, which demon-
strates their correlation with disease activity (6). Simi-
larly, other investigators (7) have reported that 95% of
patients with active TA have AECAs (7). In the present
study, we observed the overall prevalence of AAECAs to
be 86%, which is in the range of the reported prevalence
of AECAs in patients with active TA. However, unlike
the above-mentioned studies on AECAs, in our study we
observed the prevalence of AAECAs to be similar in
patients with active TA and in those with inactive TA,
which shows no correlation with disease activity. One
important reason for this could be the nonspecific
nature of existing markers of disease activity; thus, the
patients who appear to have clinically inactive disease
may actually have histologically active disease, as has
been reported previously (15). Another reason could be
that AAECAs and AECAs are directed to different
epitopes of endothelial cells, and that these epitopes
against which AAECAs are directed are also expressed
during the inactive stage of disease.
The presence of circulating AAECAs in most of
the patients with TA prompted us to investigate the
antigenic targets against which these antibodies may be
directed. We performed immunoblotting, using aortic
endothelial cell lysate as antigen, and observed that 3–5
of the 9 protein bands ranging in size from 18 kd to
200 kd were recognized by AAECAs. Of these, a triplet
of bands ranging in size from 60 kd to 65 kd was
uniformly recognized by AAECAs from all patients.
These immunoblotting results indicate that the
AAECAs that are present in patients with TA are a
heterogeneous group of antibodies directed against
multiple protein molecules of aortic endothelial cells
and may have multiple roles in the disease, depending
on the antigenic target against which they are directed.
Similar to our findings, a previous immunopre-
cipitation study on a single patient with TA showed a
broad range of HUVEC antigens (20–175 kd) recog-
nized by polyclonal AECAs. Of these HUVEC antigens,
3 predominant bands in the range of 60–65 kd were
strongly recognized by 4 of 6 monoclonal AECAs gen-
erated from the same patient and by polyclonal AECAs
as well (16). Taken together, the findings of that study
and ours suggest that the most common endothelial
antigens recognized by AAECAs or AECAs may be
Hsp60 or other homologous endothelial antigens. This
was also confirmed by our absorption study, which
showed a significant reduction in aortic endothelial cell
reactivity of Hsp60-absorbed sera. Increased expression
of Hsp60/65 in the aortic lesions of patients with TA
(17), and our previous study demonstrating a high
prevalence of anti-Hsp60/65 antibodies as well as T cell
reactivity to these heat-shock protein antigens in TA,
lend further support to this hypothesis (18).
AECAs represent an extremely heterogeneous
group of autoantibodies and are classified broadly as
antibodies to microvascular and macrovascular endothe-
lial cells, depending on the type of vasculature targeted
(19). Functionally, they may be pathogenic or nonpatho-
genic. The pathogenic antibodies may have activating,
apoptotic/cytotoxic, or both types of effects on endothe-
lial cells (20). In addition, some AECAs are directed
toward different procoagulant and anticoagulant endo-
thelial cell molecules such as thrombomodulin, heparin,
and glycoprotein IV (CD36), and induce thrombosis by
modulating the properties of these molecules (21–23).
Such AECAs are observed particularly in the setting of
microvasculopathies such as thrombotic thrombocytope-
nic purpura and scleroderma (21,23). Similarly, autoan-
tibodies present in the sera of vasculitic mice (i.e., a
murine model of vasculitis) that react with smooth
muscle cells and AECAs with such cross-reactivity may
cause aneurysm by inducing damage to smooth muscle
cells (24). Such AECAs may be observed in macrovas-
culopathies such as TA. Thus, depending on the anti-
genic targets and the type of vasculature involved,
AECAs may have different pathogenic roles in different
autoimmune diseases.
To determine whether the AAECAs that we
observed have pathogenic relevance in TA, we investi-
gated the activating potential of these antibodies in
terms of the induction of adhesion molecule expression
and cytokine production by aortic endothelial cells. Our
adhesion molecule data showed that AAECAs from all
of the patients induced endothelial up-regulation of
E-selectin and VCAM-1. Corroborating our data, most
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of the monoclonal AECAs generated from a single TA
patient were also shown to induce expression of
E-selectin and VCAM-1 on HUVECs (16). Thus,
AAECA-induced up-regulation of adhesion molecules
by aortic endothelial cells may have a critical role in
adhesion and in the arterial recruitment of circulating
inflammatory leukocytes, which in turn may cause tissue
damage through various pathways.
In the cytokine studies, we observed that
AAECAs from all of the patients with TA induced IL-4,
IL-6, and IL-8 production by aortic endothelial cells.
Previous studies in TA showing AECA-induced produc-
tion of IL-6 by HUVECs and histologic expression of
IL-6 messenger RNA (mRNA) in aortic tissues validate
our findings of AAECA-induced production of IL-6 in
patients with TA (16,25). There is no study on AECA-
induced IL-8 production in TA, but studies in Wegener’s
granulomatosis have shown AECA-induced production
of IL-8 by HUVECs (26,27). Furthermore, there are no
available studies on AECA-induced production of IL-4
in TA or other vasculitides.
Production of these inflammatory cytokines by
AAECA-stimulated aortic endothelial cells may have
important implications in TA. IL-4 is important in the
up-regulation of VCAM-1 and chemokines such as
monocyte chemotactic protein 1 by endothelial cells.
Moreover, it may cause apoptosis of endothelial cells
through the caspase 3–dependent pathway and may have
direct involvement in the induction of disease (28,29).
IL-6, in addition to up-regulating endothelial adhesion
molecules, induces humoral and cellular immune re-
sponses by mediating antibody production by B cells and
the cytotoxic activity of T cells and natural killer cells,
the main inflammatory cells involved in TA (30,31). IL-8
is a potent chemokine and may have an important role in
the recruitment of neutrophils as well as mononuclear
cells at the site of inflammation (32).
Thus, AAECA-induced production of IL-4, IL-6,
and IL-8 may, indeed, be the initial event that eventually
leads to arterial damage through different mechanisms.
AECA-induced production of TNF and IL-10 by en-
dothelial cells has not been reported in any vasculitic
disorder, including TA. We also observed no production
of TNF and IL-10 by AAECA-stimulated aortic endo-
thelial cells, which indicates that these (endothelial-
derived) cytokines may have no role in the immuno-
pathogenesis of TA. Results of previous studies in TA
that showed very weak expression of TNF mRNA in
arterial lesions also validate our findings (25).
We further investigated the apoptosis-inducing
potential of the observed AAECAs, in order to deter-
mine whether these antibodies have a direct pathogenic
effect on aortic endothelial cells. It was observed that
AAECAs from all of the patients with TA induced
apoptosis of aortic endothelial cells, and the degree of
apoptosis ranged from 20% to 39%. No data are avail-
able on AECA-mediated apoptosis or the cytotoxicity of
endothelial cells in TA, with the exception of our
previous study (33), which showed AECA-mediated
complement-dependent cytotoxicity of HUVECs. In an-
other study, we reported that 50% of AECAs possess
anti–annexin V activity, a potent inducer of endothelial
cell apoptosis, which supports the apoptosis-inducing
potential of AAECAs (12). It has also been demon-
strated that the binding of AECAs to endothelial cells
causes externalization of phosphatidylserine and induces
apoptosis of endothelial cells (34,35). Because 60-kd
endothelial antigen (Hsp60)–reactive AECAs have been
shown to cause apoptosis of endothelial cells (36,37), it
is quite likely that the AAECAs that we observed to be
directed against 60–65-kd aortic endothelial cell anti-
gens may be a subgroup of these antibodies with
apoptosis-inducing potential. The results of those stud-
ies, including the present one, collectively suggest that
the AAECAs that we observed may cause apoptotic
damage of arterial endothelium and thus may have a
direct role in the pathogenesis of TA.
In conclusion, we have shown that most patients
with TA possess circulating AAECAs that are directed
mainly against 60–65-kd endothelial cell antigens and
may have a pathogenic role in the disease via up-
regulation of adhesion molecule expression, inflamma-
tory cytokine production, and direct apoptotic damage
of arterial endothelium. Further studies in this area
would be important for a greater understanding of the
etiopathogenesis of TA.
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